Multiple Sclerosis

Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.

A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite frequent contact with patients with MS.

Patients with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS) across 4 datasets.

Most eligible people with multiple sclerosis have never used GLP-1 receptor agonists, despite their potential cardiometabolic benefits.

The OVERLORD-MS trial finds rituximab matches ocrelizumab in relapsing multiple sclerosis, with similar MRI control, relapses, and safety.

A Lancet Neurology review detailed how Epstein-Barr virus reprograms B cells to trigger multiple sclerosis in genetically susceptible carriers, and outlined the prophylactic vaccines, therapeutic vaccines, antivirals, and T-cell therapies now in clinical testing to interrupt that process.

Diagnostic delays and access barriers continue to affect patients with MS, especially in under-resourced areas, World Brain Day highlights.

AHSCT resets the immune system in highly active RRMS after high-efficacy drugs fail, delivering higher NEDA, fewer relapses, and durable function gains.

Early multiple sclerosis symptoms may start years before relapse, as genetic markers of MS, MRI changes, and neurofilament rise reveal hidden signs of MS.

There was no observed increase in risk to short- or mid-term clinically relevant infections despite the low levels of immunoglobulins.

Patients with early relapsing multiple sclerosis (MS) were able to switch to ocrelizumab after suboptimal responses to other disease-modifying therapies.

MS was not linked to worse cardiovascular surgery outcomes, though routine home discharge was lower in this population.

Most patients achieved stable or reduced lesion burden and the treatment was well tolerated by patients.

Men with multiple sclerosis (MS) were more likely to lose income earlier in life compared with women with MS.

The scoping review shows menopause and multiple sclerosis (MS) shift from fewer relapses to higher symptom burden, highlighting care gaps for older women with MS.

The disease progression of patients with MS had an association with their serum protein level.

Patients with late-onset multiple sclerosis are less likely to receive high-efficacy disease-modifying therapies than younger patients.

A multimodal AI approach could highlight areas in the brain that were associated with cognitive worsening in patients with MS.

The 5-year prediction of MS progression, defined by clinical and objective measurements, was possible with 2 machine learning tools.

Patients who were treatment naive or had switched to rituximab saw short-term results of reduced disease activity in multiple sclerosis.

Despite decreases in therapy use, hospitalizations for multiple sclerosis and neurologist visits were not affected significantly.

Lower actual wearable use was found in patients with multiple sclerosis (MS) despite comparable intentions to use the wearable technology.

Smoking cessation, abnormal weight, and socioeconomic deprivation were all associated with mortality in multiple sclerosis.

Patients with multiple sclerosis valued both occupational therapy and physiotherapy as means of addressing their condition.

Severe COVID-19 was rare in patients with multiple sclerosis even when vaccine responses were impaired.